Quantbot Technologies LP Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quantbot Technologies LP increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 678.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,588 shares of the biopharmaceutical company's stock after buying an additional 1,384 shares during the period. Quantbot Technologies LP's holdings in Alnylam Pharmaceuticals were worth $374,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $1,045,822,000. Geode Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company's stock valued at $589,209,000 after buying an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company's stock valued at $120,940,000 after buying an additional 26,614 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after buying an additional 8,462 shares during the period. Finally, Royal London Asset Management Ltd. raised its position in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Royal London Asset Management Ltd. now owns 281,509 shares of the biopharmaceutical company's stock worth $66,242,000 after acquiring an additional 1,759 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. This represents a 4.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Royal Bank of Canada upped their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $316.25.

Alnylam Pharmaceuticals Stock Up 4.3 %

Shares of NASDAQ:ALNY traded up $11.07 during mid-day trading on Wednesday, hitting $266.83. 886,904 shares of the company traded hands, compared to its average volume of 834,477. The stock has a market cap of $34.71 billion, a P/E ratio of -122.96 and a beta of 0.30. The stock has a 50-day moving average price of $260.16 and a two-hundred day moving average price of $260.56. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.